TRAWS PHARMA INC

TRAWNASDAQ

🏆 #3783 by market capEarnings Aug 13US Equity

$0.54▲ $0.00 (+0.19%)

🌙 After hours$0.55▲ 0.74%Regular close · extended-hours price shown

1h—

24h▲ 0.2%

7d—

14d—

30d—

1y—

🏦Market Cap

$8M

Small Cap

📈Revenue Growth (YoY)

+1104.0%

High Growth

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

2.9x

Cheap

Otter Score

Weak

No chart data available for TRAW.

Trading Snapshot

Day Range: $0.54 – $0.55
52-Week Range: $0.43 – $3.27
Volume: $2.22B
Avg Volume: $2.36B
Shares Outstanding: 15.2M
Next Earnings: Sep 15, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $760,740
P/E Ratio: —
P/S Ratio: 2.9x
EPS (TTM): $-2.07
Dividend Yield: —

Why Investors Own TRAW

✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
✓Healthy economics — 50% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▲ +7.9% YoY

Gross Margin (TTM)

50.2%▲ +3.0% YoY

Operating Income (TTM)

$733,770▲ +7.9% YoY

Free Cash Flow (TTM)

$675,180▲ +7.9% YoY

About TRAWS PHARMA INC

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

🦦